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How the brainmonitors ongoing behavior for performance errors is a central question of cognitive neuroscience. Diminished awareness
of performance errors limits the extent to which humans engage in corrective behavior and has been linked to loss of insight in a number
of psychiatric syndromes (e.g., attention deficit hyperactivity disorder, drug addiction). These conditions share alterations in mono-
amine signaling that may influence the neural mechanisms underlying error processing, but our understanding of the neurochemical
drivers of these processes is limited.We conducted a randomized, double-blind, placebo-controlled, cross-over design of the influence of
methylphenidate, atomoxetine, and citalopram on error awareness in 27 healthy participants. The error awareness task, a go/no-go
response inhibition paradigm, was administered to assess the influence of monoaminergic agents on performance errors during fMRI
data acquisition. A single dose of methylphenidate, but not atomoxetine or citalopram, significantly improved the ability of healthy
volunteers to consciously detect performance errors. Furthermore, this behavioral effect was associated with a strengthening of activa-
tion differences in the dorsal anterior cingulate cortex and inferior parietal lobe during the methylphenidate condition for errors made
with versuswithout awareness. Our results have implications for the understanding of the neurochemical underpinnings of performance
monitoringand for thepharmacological treatmentof a rangeofdisparate clinical conditions that aremarkedbypoor awarenessof errors.
Introduction
The neural basis of error-processing has become a key research
interest in cognitive neuroscience, not only because of its rele-
vance to human cognitive performance but also because dysfunc-
tion of self-monitoring is seen in a range of clinical conditions,
such as traumatic brain injury (TBI), schizophrenia, attention
deficit hyperactivity disorder (ADHD), and drug addiction
(Carter et al., 2001; Kaufman et al., 2003; Rubia et al., 2005;
O’Keeffe et al., 2007). In these conditions, diminished awareness
of errors has been linked to clinical symptoms, such as inatten-
tion, poor insight, and perseverative behavior, which in turn are
predictors of poor treatment outcome and functional recovery
(Mintz et al., 2004; O’Keeffe et al., 2004). Despite the clear im-
perative to understand and remediate such deficits, the issue of
awareness, and its instantiation in the brain, has been primarily
overlooked.
Recent electrophysiological work has demonstrated that the
early stages of error processing are preconscious and are unaf-
fected by an individual’s awareness of that error but later process-
ing stages are only initiated if the error is consciously perceived
(Nieuwenhuis et al., 2001;O’Connell et al., 2007; Steinhauser and
Yeung, 2010). This distinction has implications previous studies
that have shown abnormalities in error-related activity in a range
of clinical groups without controlling for potential differences in
error awareness. Studies that have contrasted errors that partici-
pants were or were not aware of have identified a bilateral net-
work of frontal and parietal regions (Nieuwenhuis et al., 2001;
Hester et al., 2005; Klein et al., 2007). Interestingly, this work has
failed to show a predictive relationship between dorsal anterior
cingulate cortex (dACC) activity and error awareness (Hester et
al., 2005; Klein et al., 2007), despite this region having a central
role in models of performance monitoring and its dysfunction in
a range of clinical disorders that involve awareness deficits.
Current models of performance monitoring argue that a pha-
sic decrease in midbrain dopamine (DA) provides a reward-
prediction error to the dACC, which coordinates post-error
adaptation of behavior (Holroyd and Coles, 2002). Othermodels
have suggested roles for norepinephrine (NE) (Nieuwenhuis et
al., 2005) and serotonin (5-HT) (Cools et al., 2008) in perfor-
mance monitoring (Jocham and Ullsperger, 2009). Pharmaco-
logical manipulations of error-related brain activity have shown
that enhancing catecholamines with amphetamine (de Bruijn et
al., 2004; de Bruijn et al., 2006) or the!2 adrenoceptor antagonist
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yohimbine (Riba et al., 2005) increased the amplitude of the
error-related negativity (ERN).Methylphenidate (MPH) has also
been shown to be effective in treating the cognitive deficits asso-
ciated with TBI (Willmott and Ponsford, 2009), in which there is
a fundamental problem of reduced awareness (O’Keeffe et al.,
2004). In contrast, the D2 receptor antagonist haloperidol (Zirn-
held et al., 2004) and the GABAA/benzodiazepine receptor mod-
ulators lorazepamand oxazepam (Johannes et al., 2001; de Bruijn
et al., 2004) have been shown to decrease error-related dACC
activity. Crucially, because the cognitive paradigms used in these
studies did not explicitly test for conscious awareness of errors,
one cannot disambiguate the effects of the pharmacological ma-
nipulation on preconscious versus conscious error processing.
Monoamine reuptake inhibitors, such as MPH, atomoxetine
(ATM), and citalopram (CIT), are routinely used to treat clinical
disordersmarked by poor error awareness.Herewe examined the
effect of a single acute dose of MPH, ATM, CIT, and placebo
(PLAC) using a randomized, placebo-controlled, crossover de-
sign on the proportion of behavioral errors that escaped con-
scious awareness.
Materials andMethods
Subjects. Twenty-seven male subjects (mean age, 22 years; range, 18–35
years)were recruited for this study via advertisements at theUniversity of
Queensland (Brisbane, QLD, Australia). All participants were right
handed and were excluded if they reported any history of psychiatric or
neurological illness, including head injury, previous usage of psychotro-
pic medication, or significant drug use [significant was defined as fol-
lows: (1) use of any illicit substances within the lastmonth; (2)more than
five lifetime intake of any illicit drug except cannabis; and (3) more than
monthly cannabis intake], smoking (more than five cigarettes per week),
or alcohol dependence (!24 units per week). Before commencing, all
participants were screened by a consultant psychiatrist who also admin-
istered the M.I.N.I. Screen (Sheehan et al., 1998) and the Kessler K10
(Kessler et al., 2003).
All participants were recruited according to the principles of the Dec-
laration of Helsinki and in accordance with the ethical guidelines of the
University of Queensland and the Wesley Hospital (Brisbane, QLD,
Australia).
Drug administration. Participants were tested on the same day and at
the same time for 4 consecutive weeks. On each occasion, the participant
ingested with water (in a randomized order) a single blue gelatin capsule
containing 30 mg of MPH, 60 mg of ATM, 30 mg of CIT, or PLAC
(dextrose). Dosage selection was based on clinically relevant doses for
ADHD (Spencer et al., 1998; Michelson et al., 2003) and depression, as
well as on data from previous acute challenge studies that have demon-
strated neurocognitive effects of these drugs (Nathan et al., 2000; Aron et
al., 2003; Chamberlain et al., 2006)
All participants were required to fast for at least 1 h before drug ad-
ministration. Caffeine was not to be consumed on test days. After drug
administration, subjects rested in a quiet waiting room for 90min before
commencing. From minutes "90 to "150 (after administration), sub-
jects undertook the fMRI experiment testing error awareness. Task tim-
ing was based on the region of concomitant peak plasma levels for the
three study drugs (#90–180 min after oral ingestion in adults) (Kragh-
Sorensen et al., 1981; Henning and Netter, 2002; Sauer et al., 2005) and
on findings from previous neurocognitive studies (Aron et al., 2003;
Chamberlain et al., 2006). Data on the influence of these agents on sub-
jective (visual analog scales) and physiological measures (e.g., blood
pressure) are presented.
Behavioral task. To examine conscious recognition of errors, we ad-
ministered the error awareness task (EAT) (Fig. 1) (Hester et al., 2005), a
motor go/no-go response inhibition task in which subjects make errors
of commission of which they are aware (aware errors) or unaware (un-
aware errors). Using this task, we have previously examined the neural
mechanisms associated with error awareness (Hester et al., 2005;
O’Connell et al., 2007), as well as the diminished awareness of perfor-
mance errors in ADHD (O’Connell et al., 2009) and drug addiction
(Hester et al., 2007). The EAT presents a serial stream of single color
words, with the word presented for 800 ms followed by a 700 ms inter-
stimulus interval. Participants were trained to respond to each of the
words with a single “go trial” button press and withhold this response
when either of two different circumstances arose. The first circumstance
arose if the same word was presented on two consecutive trials (“repeat
no-go”) and the second if the word and its font color matched (“color
no-go”) rather than the typical word and color incongruency (for exam-
ples, see Fig. 1). By having two competing types of response inhibition,
we aimed to vary the strength of stimulus–response relationships,
whereby representations of rules competitively suppress one another
such that themore prepotent rule would suppress the weaker rule and so
produce a significant number of errors, a small proportion of whichmay
go unnoticed as a result of focusing primarily on the prepotent rule. To
indicate “error awareness,” participants were trained to forego the regu-
lar go-trial button response (left) and instead to make a non-speeded
responsewith the alternative (right) button on the trial immediately after
a commission error. Although the online assessment of error awareness
Figure 1. The EAT. The EAT presents a serial stream of single color words in incongruent fonts, with theword presented for 800ms followed by a 700ms interstimulus interval. Participants were
trained to respond to each of the words with a single go trial (left) button press and to withhold this response when either of two different circumstances arose. The first was if the same word was
presented on two consecutive trials (repeat no-go), and the secondwas if theword and font of thewordmatched (color no-go). To indicate error awareness, participants were trained to forego the
regular go-trial button response (left; L) and instead to respond with the alternative (right; R) button after any commission error. Past studies have demonstrated that error-related BOLD signal is
uninfluenced by the awareness response itself (Hester et al., 2005). Although levels of awareness undoubtedly vary on a continuum,wemade a qualitative distinction between aware and unaware
errors to facilitate our event-related fMRI analysis.
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required that the participant make an additional overt response, control
experiments with the EAT have ruled out the possibility that error-
related brain activity might be contaminated by this additional response
demand (Hester et al., 2005; O’Connell et al., 2007).
Before entering the MRI scanner, participants practiced two novel
blocks of the task to ensure they understood the task instructions. Six
blocks of 225 trials (200 go trials, 25 no-go trials) for a total of 1350 trials
were administered duringMRI data collection. An equivalent number of
color and repeat no-go trials were administered across the six blocks for
a total of 75 repeat and 75 color no-go trials. All aspects of stimulus
delivery and response recording were controlled by E-Prime software
(version 1.1; Psychology Software Tools) running on a laptop computer,
which was interfaced with the MR scanner during acquisition of fMRI
data. Participants responded to each stimulus using their right hand,
entering their response on anMR-compatible response box (Fiber-Optic
response pads; Current Designs).
Scanning parameters. FunctionalMR imageswere acquired at theWes-
ley Hospital (Auchenflower, Brisbane, QLD, Australia) using a whole-
body 1.5 tesla Siemens Sonata scanner with a gradient-echo echo-planar
imaging (EPI) sequence. The quadrature transmit-receive radiofre-
quency head coil was for signal acquisition. Echo planar images were
acquired using a gradient-echo pulse sequence and sequential slice ac-
quisition (TR, 2000ms; TE, 30 ms; flip angle, 90°; 29 contiguous slices of
3 mm thickness; 10% gap; in-plane resolution of 3.6 $ 3.6 pixels in a
FOV of 384 mm). A total of 174 EPI volumes were collected for each
functional run, and a total of six functional runs were performed for each
participant, during each of the four sessions. Activation data were regis-
tered to high-resolution T1-weighted isotropic (1 mm3) structural
MPRAGE images, collected during each of the four sessions, to localize
the pattern of physiological changes associated with the task.
Data analysis. Behavioral data from each participant were used to
categorize the no-go trial events for each drug session into successful
responses (stops), aware errors, and unaware errors. All analyses were
conducted using AFNI software (http://afni.nimh.nih.gov/afni/)(Cox,
1996). After image reconstruction, the time-series data weremotion cor-
rected using 3D volume registration (least-squares alignment of three
translational and three rotational parameters). Activation outside the
brain was removed using edge detection techniques.
Separate hemodynamic impulse response functions (IRFs) at 2 s tem-
poral resolution were calculated using deconvolution techniques for
aware errors, unaware errors, and stop events. Response functions for all
regressor events were initiated at image acquisition onsets because the
presentation of all epochs-of-interest was timed to coincide with the
beginning of the 2 s TR cycle. A nonlinear regression program deter-
mined the best-fitting gamma-variate function for these IRFs as de-
scribed previously (Murphy and Garavan, 2005). The area under the
curve of the gamma-variate functionwas expressed as a percentage of the
area under the baseline. The baseline in this design is an implicit one and
is indicative of task-related go-trial processing that remains after the
variance related to the other types of events have been removed.
The percentage area (event-related activation) map voxels were resa-
mpled at 1 mm3 resolution, then spatially normalized to standard MNI
space (MNI 152 template), and spatially blurred with a 3 mm isotropic
root mean squared Gaussian kernel. Group activation maps for event
type (errors, stops) were determined with one-sample t tests against the
null hypothesis of zero event-related activation changes (i.e., no change
relative to baseline). The above procedures were applied to each of
the four drug sessions independently, so that group maps of errors were
available for each of the four conditions. Significant voxels within group
maps passed a voxelwise statistical threshold (t% 4.69, p" 0.00001) and
were required to be part of a larger 72#l cluster of contiguous significant
voxels. By using a combination of probability thresholding and cluster
thresholding, the aim is tomaximize the power of the statistical test while
holding the likelihood of false positives to aminimum. To determine the
cluster threshold, we use a program called 3dClustSim. The program is
provided with the number of voxels in the group map, the spatial corre-
lation of voxels (must be contiguous on three sides), and the voxelwise
threshold. The program then runs a series of Monte Carlo simulations
(10,000 iterations for our study) to determine the frequency of clusters of
varying sizes produced by chance. From this frequency distribution, we
then select the cluster size (72#l given our parameters) that occurs&1%
of the time by chance, to give a threshold of p% 0.01 (corrected).
The comparison of interest was between aware and unaware errors.
Because of the significant behavioral effect of MPH on error awareness,
the activation clusters from whole-brain analyses of errors in both the
PLAC and MPH conditions were used to create an OR map for the
purposes of a region-of-interest (ROI) analysis. An OR map includes
the voxels of activation indicated as significant from either of the constit-
uent maps. The mean activation for clusters in the combined error map
was then calculated for the purposes of an ROI analysis, deriving mean
activation levels for aware and unaware errors in each of the conditions,
which were compared using repeated-measures t tests, corrected via a
modified Bonferroni’s procedure for multiple comparisons (Keppel,
1991). To examine the specificity of this effect, we also performed the
same analysis on the OR map of ATM and PLAC conditions.
Results
Behavioral results
Performance indices from the EAT for all four drug conditions
are presented in Figure 2 and Table 1. Tests of normality revealed
that behavioral measures of inhibition accuracy and error aware-
ness from the EAT task were not normally distributed, and these
were transformed using an arcsine function before analysis with
parametric analyses. The proportion of EAT no-go inhibition
errors of which participants (n% 27) indicated awareness during
each of the four drug conditions (MPH, ATM, CIT, and PLAC)
was examined using repeated-measures ANOVA. A significant
main effect of drug condition was present (F(3,78) % 10.28, p &
0.001), with participants aware of a significantly higher pro-
portion of errors in the MPH condition when compared with
PLAC (p& 0.008, Bonferroni’s adjusted probability threshold
corrected for multiple post hoc comparisons; Cohen’s d' %
2.34), ATM, or CIT conditions. ATM was also associated with
an improvement in error awareness compared with PLAC
(p % 0.046), although this effect did not survive Bonferroni’s
adjustment.
There was a trend for response inhibition accuracy on no-go
trials to differ as a function of drug condition (F(3,78)% 2.32, p%
Figure 2. Behavioral performance on the EAT. A, The proportion of errors for which partici-
pants (n% 27) indicated awareness of errors as a function of the four drug conditions: MPH,
ATM, CIT, and PLAC. A significant main effect of drug condition was present (F(3,78)% 10.28,
p& 0.001). Participants were aware of a significantly higher proportion of errors in the MPH
condition than in thePLAC, ATM, or CIT conditions (*p&0.008 for all comparisons, Bonferroni’s
adjusted). B, The percentage of successful response inhibitions on EAT no-go trials during each
of the four drug conditions. There was a trend toward a main effect of drug condition on the
percentage of response inhibition errors (F(3,78)% 2.32, p% 0.08).
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0.08). Exploratory post hoc analysis demonstrated significant im-
provement in response inhibition in the MPH condition when
compared with PLAC (p% 0.009, Cohen’s d' % 0.40). Consistent
with previous use of this task (Hester et al., 2005; O’Connell et al.,
2007), individual differences in response inhibition performance
were not associated with awareness of errors (PLAC, r%(0.04,
p% 0.84; MPH, r% 0.02, p% 0.91).
The influence of no-go type (repeat, color) on error awareness
and response inhibition accuracy was also examined in separate 2
(no-go type) $ 4 (drug) repeated-measures ANOVAs. Error
awareness rates showed a significant main effect of no-go type
(F(1,26)% 19.9, p% 0.01), with poorer awareness of repeat errors
comparedwith color, an effect previously demonstratedwith this
task (Hester et al., 2009). There was, however, no significant in-
teraction between no-go type and drug condition for error
awareness rates (F(3,78)% 0.52, p% 0.67). The comparable anal-
ysis for successful response inhibition demonstrated a significant
main effect of no-go type (F(1,26)% 66.6, p% 0.01), with accuracy
significantly higher for repeat no-go trials compared with color
[also replicating a previous finding (Hester et al., 2009)] but again
no interaction between no-go type and drug condition (F(3,78)%
1.76, p% 0.19).
There was neither a significant main effect of drug condition
on go trial response time (RT) (F(3,78)% 0.59, p% 0.62) nor no-go
error RT (F(3,78) % 1.41, p % 0.24). Although no-go error RT
significantly differed between aware and unaware errors (F(3,66) %
11.5, p% 0.003), there was no interaction with drug condition
(F(3,66) % 2.24, p % 0.14).
Post-error RTs showed two distinct patterns consistent with
previous use of this task (Hester et al., 2005, 2007), with faster RT,
or speeding up, after an aware error (post-aware error go trial
RT( pre-aware error go trial RT%(150.6 ms) and slower RT
after an unaware error (post-unaware error go trial RT ( pre-
unaware error go trial RT % 52.9 ms). Post-aware error RT was
significantly faster than post-unaware error RT (F(1,21) % 156.8,
p% 0.01), but drug condition did not have a significant effect on
either post-aware error RT (F(3,78) % 1.8, p % 0.15) or post-
unaware error RT (F(3,63) % 1.5, p % 0.21). The interaction be-
tween drug condition and post-error RT changes was also
nonsignificant (F(3,63) % 0.72, p % 0.54). It is important to note
that the speeding of post-aware error responses is confounded by
subjects providing the alternate “awareness” button press (in
which the go stimulus is ignored), but a similar pattern of signif-
icantly faster RT was observed for the second go trial after an
aware error.
Effects of drug on subjective ratings and blood pressure
Participants completed visual analog scales (Norris, 1971; Bond
and Lader, 1974) to assess possible drug effects on subjective
alertness, contentedness, and calmness. Sixteen opposing subjec-
tive states were rated at baseline and "90 and "180 min after
capsule administration. A log transformation was applied to the
items. Factors of “alertness,” “contentedness,” and “calmness”
were calculated by taking the mean transformed score across
loading items for each time point. Each factor was then subject to
a 4 (drug) $ 3 (time) repeated-measures ANOVA. Crucially,
there were no significant drug $ time interactions (alertness,
F(6,156)% 1.14, p! 0.05; contentedness, F(6,156)% 0.50, p! 0.05;
calmness, F(6,156)% 1.41, p! 0.05).
Blood pressure was also recorded at baseline and then again at
time points"60 and"180 min. There was a significant drug$
time-point interaction for systolic blood pressure (drug$ time,
F(6,150)% 2.23, p& 0.05). Simple effects revealed an effect of time
onMPH, (F% 4.25, p% 0.026).Post hoc tests showed that systolic
blood pressure was significantly higher at "180 min (mean %
142.62) relative to baseline (mean % 136.12). No other simple
effects were significant (p ! 0.05). There were no significant
drug $ time interactions for diastolic blood pressure (drug $
time, F(6,132)% 1.18, p! 0.05).
Imaging data: errors
The event-related functional analysis of BOLD activity associated
with errors revealed 12 clusters of activity that differentiated
aware from unaware errors (see Table 2). In contrast with null
results from previous studies (Nieuwenhuis et al., 2001; Hester et
al., 2005; Klein et al., 2007; O’Connell et al., 2007), we identified
an activity cluster in the dACC region (x%(1, y% 9, z% 41) that
also showed significantly greater activity during aware versus un-
aware errors (Fig. 3). This effect appeared consistently and ro-
bustly across drug conditions, with the difference between aware
and unaware error activity within this dACC ROI significant for
each of the drug conditions (Fig. 3).
To examine the association between changes in BOLD activity
and the behavioral improvement in awareness during the MPH
condition, we tested for interaction effects, focusing on the com-
parison between MPH and PLAC in which behavioral effects
were maximal. Error-related ROIs from the group maps of the
PLAC and MPH conditions were combined, including all signif-
icant voxels from the two constituent maps (Hester et al., 2005),
to examine mean BOLD activity during each of the four event
Table 1. Mean accuracy, RT, and SE of measurement scores for participants
(n! 27) during the four drug conditions of the EAT
Placebo Methylphenidate Atomoxetine Citalopram
Category M SEM M SEM M SEM M SEM
No-go accuracy (% correct) 50.2 4.2 54.2 4.6 47.9 4.7 47.4 4.2
Error awareness (% of aware
errors)
80.5 2.4 91.1 1.9 85.1 2.1 81.8 1.9
Go RT (ms) 428.5 18.2 422.7 19.8 408.6 21.2 430.2 20.8
No-go error RT (ms) 467.2 23.9 443.8 20.1 428.4 21.2 457.5 25.6
Aware error RT (ms) 458.1 22.2 433.4 20.6 417.2 23.8 437.6 25.1
Unaware error RT (ms) 508.9 37.1 511.6 36.6 448.2 28.6 461.2 30.4
Post-aware( pre-aware error RT
(ms)
(0.142.6 16.9 (164.4 17.2 (135.4 18.2 (146.6 17.2
Post-unaware( pre-unaware
error RT (ms)
36.5 12.2 23.1 16.5 95.1 42.3 57.1 17.1
Post-aware (n" 2)( pre-aware
error RT (ms)
(88.3 10.2 (84.8 9.6 (86.4 10.7 (88.0 9.3
M, Mean.
Table 2. Regions of error-related BOLD activity in the PLAC conditionmapwhose
level of activity differentiated aware from unaware errors
MNI coordinates
Brain region Volume (#l) x y z
Aware errors! unaware errors
L Inferior parietal 3984 (46 (36 47
L Anterior cingulate 2082 (1 9 41
L Supplementary motor area 1952 (2 (11 55
R Inferior parietal 1855 48 (52 36
L Precuneus 1718 (1 (75 33
L Insula 332 (53 10 8
R Supramarginal 278 50 (30 38
R Insula 258 44 11 1
R Inferior parietal 191 38 (42 42
R Cerebellum 141 16 (53 (23
L Precentral 91 (27 (28 70
R Inferior frontal 80 52 3 36
L, Left; R, right.
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types. Because of the improvement in error awareness withMPH,
five participants had insufficient unaware error events for inclu-
sion in this analysis. The resulting interaction analysis was there-
fore based on the remaining 22 participants. We note that the
benefit to error awareness conferred by MPH, relative to PLAC,
remained significant in this subsample (F(1,21)% 31.9, p& 0.001)
We used a two-drug condition (PLAC, MPH) $ 2 error type
(aware, unaware) repeated-measures ANOVA to compare aware
and unaware error-related activity during the PLAC and MPH
conditions. Significantmain effects for drug conditionwere iden-
tified in the right middle frontal, left insula, and right inferior
frontal regions, with all clusters showing significantly greater ac-
tivity during theMPHconditionwhen comparedwith PLAC (see
Table 3). Consistent with the results from the PLACmap, signif-
icant main effects of awareness were detected in bilateral inferior
parietal, left insula, bilateral precuneus, bilateral middle frontal,
right temporal, right cerebellar, and right angular gyrus regions.
All regions showed significantly greater activity during aware er-
rors when compared with unaware errors. The three regions
showing main effects for the effect of MPH did not differentiate
aware from unaware errors.
Only two clusters demonstrated significant interaction effects:
the left inferior parietal lobe (IPL) and the dACC (Fig. 4). Both
regions demonstrated the same pattern of activity, wherebyMPH
produced an increase in aware error activity (relative to PLAC)
and a decrease in unaware error activity (relative to PLAC).
To clarify the neuroanatomical specificity of the effect ofMPH
on activity differences in the left IPL and dACC, we performed
two additional analyses, this time comparing changes in BOLD
activity and behavioral improvement in awareness during the
ATM condition. First, we repeated the steps from above and sub-
stituted the ATMcondition for theMPH. Significantmain effects
for drug conditionwere identified in six regions, the right inferior
parietal, left insula, left caudate, posterior cingulate, left supra-
marginal, and right middle frontal, with all clusters showing sig-
nificantly greater activity during the ATM condition when
compared with PLAC (Table 4). Consistent with the results from
the PLAC map, significant main effects of awareness were de-
tected in bilateral inferior parietal, left insula, bilateral precuneus,
bilateral middle frontal, right temporal, right cerebellar, and tha-
lamic regions. All regions showed significantly greater activity
during aware errors when compared with unaware errors.
Two regions (Fig. 4C,D), the left inferior frontal gyrus (IFG)
(MNI: x%(54, y% 3, z% 13) and right inferior temporal gyrus
(ITG) (x % 56, y % (54, z % (6), demonstrated significant
interaction effects. Both regions showed the same pattern of ac-
tivity, whereby ATMwas associated with a large increase in aware
error activity (relative to PLAC) and a small decrease in unaware
error activity (relative to PLAC).
Second, we used the ROIs from the PLAC condition group
map to compare activity in a 2 $ 3 repeated-measures ANOVA
for awareness-related changes in BOLD activity as a function of
the three drug conditions (PLAC, ATM, MPH). Three regions
showed a significant interaction effect (Fig. 5), two in closely
aligned regions to those identified in the PLAC and MPH com-
parison, namely the left IPL (MNI: x % (45, y % (36, z % 47)
and dACC (MNI: x%(1, y% 9, z% 41), as well as the right IPL
(MNI: x% 48, y%(52, z% 36). The difference in BOLD activity
between aware and unaware errors was significantly greater in the
MPHcondition thanPLAC (p% 0.047, corrected), whereas ATM
was not significantly different from PLAC (p% 0.86).
Our results therefore suggest a neuroanatomical dissociation
in terms of the effect of MPH and ATM on awareness-related
brain activity. Whereas robust enhancement of error awareness
by MPH was mediated by activity differences within the dACC
and left IPL, the relatively more subtle effects of ATM were me-
diated by activity differences within the left IFG and right ITG.
Discussion
The results of this study demonstrate the pharmacological en-
hancement of conscious error awareness. A single, clinically rel-
evant dose ofMPHwas able to considerably (10%) improve error
Figure 3. Activity within the dACC differentiates errors made with and without awareness.
Bar graphs represent the mean BOLD percentage signal change for aware and unaware errors
during the PLAC condition. A significant main effect of awareness on error-related ACC activity
was observed during the PLAC condition, along with the three other drug conditions. The MNI
coordinates for the dACC cluster region are listed in the title, and the sagittal 3D-rendered view
of the activity cluster is taken from the MNI center-of-mass x-coordinate (x%(1).
Table 3. Regions of error-related BOLD activity in the combined PLAC andMPH OR
map demonstrating significant main effects of drug condition or error awareness
MNI coordinates
Brain region Volume (#l) x y z
Aware errors! unaware errors
L Inferior parietal 6569 (43 (39 51
R Inferior parietal 2674 48 (51 39
L Anterior cingulate 1632 (1 15 39
L Supplementary motor area 901 (2 (12 56
R Middle temporal 535 56 (51 3
R Precuneus 437 5 (74 33
R Temporal 304 50 11 2
L Supramarginal 221 (56 (26 25
L Precuneus 203 (8 (77 32
L Inferior frontal 152 (56 11 8
L Inferior frontal 145 (57 1 11
R Cerebellar 144 19 (54 (24
R Angular 132 52 (55 21
MPH! placebo
R Middle frontal 438 27 42 34
L Insula 172 (35 16 (4
R Inferior frontal 142 52 8 16
L, Left; R, right.
Hester et al. • Neurochemical Enhancement of Error Awareness J. Neurosci., February 22, 2012 • 32(8):2619–2627 • 2623
awareness in nonclinical adults compared with ATM, CIT, and
PLAC. The beneficial effect of MPH was specific to error aware-
ness, without concomitant changes in response speed. Crucially,
this behavioral improvement in error awareness was under-
pinned by physiological changes within the dACC and IPL, with
activity differences between aware and unaware trials being sig-
nificantly larger under MPH than under PLAC.
Holroyd and Coles (2002) have argued that performance
monitoring is dependent on ascending mesencephalic DA pro-
jections that transmit predictive error signals via the basal ganglia
to the ACC. The results of the current study are broadly consis-
tent with this hypothesis, because the indirect DA agonist MPH,
which has been shown to increase DA levels within subcortical
regions, including the striatum and basal ganglia (Volkow et al.,
2005), was able to modulate activity within the dACC and pro-
mote conscious error awareness.
Although MPH is often viewed as an exclusive DA reuptake
inhibitor, in common with ATM it has profound effects on NE
signaling in prefrontal cortex (PFC) via reuptake inhibition of the
NE transporter (Berridge et al., 2006). A potential role for NE in
error processing is indicated by the strong reciprocal connections
between the PFC, ACC, and the locus ceruleus (LC) arousal sys-
tem. The LC also provides a strong phasic response to transient
decreases in performance and serves to boost task-specific repre-
sentations in top-down control regions (Aston-Jones andCohen,
2005; Nieuwenhuis et al., 2005). Intracranial recordings in mon-
keys have demonstrated that the magnitude of phasic NE cell
firing is determined by tonic activity levels in the LC (Aston-Jones
and Cohen, 2005), and important relationships between error
awareness and arousal have been reported previously. For exam-
ple, awareness of errors on the EAT is reduced by task manipula-
tions that engender attentional drift (Shalgi et al., 2007) and is
inversely correlated with tonic EEG measures of cortical arousal
(O’Connell et al., 2007). These models further propose that the
balance between tonic and phasic modes of LC/NE activity is
driven by a representation of current task utility that may be DA
dependent (Aston-Jones and Cohen, 2005). Thus, the beneficial
effect of MPH, and intermediate effect of ATM, on error aware-
ness is consistent with the view that DA and NE are likely to play
overlapping, complimentary roles in the processing of errors (Jo-
cham and Ullsperger, 2009).
Figure 4. BOLD activity clusters for aware versus unaware errors demonstrating anatomically dissociable effects of MPH and ATM. The dACC activity cluster (A) (MNI coordinates: x%(1, y%
15, z% 39) and left IPL cluster (B) (MNI coordinates: x%(44, y%(39, z% 51) demonstrating a significant interaction effect between error awareness (aware, unaware) and drug condition
(MPH, PLAC). The left IFG (C) (MNI coordinates: x%(54, y% 3, z% 13) and right ITG (D) (MNI coordinates: x% 56, y%(54, z%(6) represent the regions showing a significant interaction
between ATM and error awareness. Bar graphs represent themean BOLD percentage signal change (relative to baseline) for aware and unaware errors, for theMPH, ATM, or PLAC conditions. Error
bars represent the SEM. L, Left; R, right.
Table 4. Regions of error-related BOLD activity in the combined PLAC and ATM OR
map demonstrating significant main effects of drug condition or error awareness
MNI coordinates
Brain region Volume (#l) x y z
Aware errors! unaware errors
L Postcentral 11716 (41 (33 50
R Inferior parietal 4615 46 (50 39
L Middle cingulate 4266 (2 (2 45
L Precuneus 1846 1 (72 39
R Inferior frontal 1667 43 8 8
R Cerebellum 1492 26 (53 (22
R Thalamus 1359 8 (15 14
L Inferior frontal 909 (54 3 12
L Thalamus 880 (12 (21 9
R Inferior temporal 849 55 (52 (2
L Insula 759 (38 13 5
R Superior frontal 663 21 (13 60
L Cerebellum 371 (35 (46 (24
L Caudate 316 (13 (5 16
R Posterior cingulate 279 2 (32 26
L Supramarginal 251 (56 (50 27
R Middle frontal 136 33 27 37
R Middle frontal 116 41 28 31
R Supplementary motor area 108 10 (10 68
ATM! placebo
R Inferior parietal 4615 46 (50 39
L Insula 759 (38 13 5
L Caudate 316 (13 (5 16
R Posterior cingulate 279 2 (32 26
L Supramarginal 251 (56 (50 27
R Supplementary motor area 108 10 (10 68
L, Left; R, right.
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A possible noradrenergic influence on error processing is also
supported by the nominally significant effect of ATM compared
with PLAC. ATM also strengthened awareness-related brain ac-
tivity but within a distinct set of awareness-related regions to
those targeted by MPH. The enhancement of IFG activity by
ATM is consistent with known NE inputs and expression of the
NE transporter within PFC (Arnsten, 2011). Our result is also
consistent with a previous study that examined the impact of an
acute dose of ATM (80 mg) versus PLAC on error monitoring
and reported drug-related activity changes in the IFG (Graf et al.,
2011). Together, our study suggests dissociable neural pathways
by whichMPH and ATMmay improve conscious error awareness.
Notwithstanding evidence thatMPHmodulates catecholamine sig-
naling in PFC, the functional dissociations underpinning error
awareness reported here recapitulate the known expression patterns
of themolecular targets ofMPH andATM. Thus,MPH inhibits the
action of DA transporter within the mesencephalic DA system pro-
jecting to the ACC, whereas ATM inhibits the action of NE trans-
porterwithin prefrontal but not subcortical regions (Bymaster et al.,
2002). Future studies should assess the po-
tential clinical utility of these findings.
The results of the current study show
that enhancing catecholamine neu-
rotransmission with MPH produces a
more robust error signal within the ACC
and inferior parietal cortex and that this
same enhancement significantly increases
the likelihood that errors will be con-
sciously perceived. The specificity and size
of the MPH effect on error awareness in
healthy adults is directly relevant to the
treatment of performance monitoring
and insight deficits identified in clinical
conditions. For example, MPH is rou-
tinely used to treat ADHD and has been
more recently trialed as a treatment for
cocaine dependence (Castells et al., 2007).
These groups are known to demonstrate
impaired error awareness (Hester et al.,
2007; O’Connell et al., 2009) and dimin-
ished error-related neural activity in re-
gions including the dACC (Kaufman et
al., 2003; Rubia et al., 2005), with the level
of impairment associated with increased
symptom severity (Moeller et al., 2010).
Recent evidence suggests that MPH sig-
nificantly increases ACC activity in
ADHD and cocaine dependence (Jonk-
man et al., 2007; Goldstein et al., 2010; Li
et al., 2010). It is not known, however,
whether chronic use of MPH during typ-
ical treatment regimens has beneficial
effects for error awareness or clinical
symptomatology. Given the relationship
between the severity of awareness deficits
and clinical symptoms in psychiatric con-
ditions, the current data highlight the po-
tential for such medications to enhance
error awareness and in turn improve clin-
ical outcomes.
The absence of any significant influ-
ence of CIT on behavioral or imaging
measures of error processing is consistent
with previous pharmacologic studies examining the acute effect
of other drugs thought to influence the serotonergic system (de
Bruijn et al., 2004, 2006). Previous studies using acute tryptophan
depletion to perturb the serotonergic system had found a nega-
tive impact on dorsomedial PFC during cognitive control tasks,
in both humans (Evers et al., 2006) and rats (Narayanan and
Laubach, 2008), potentially implicating this system in perfor-
mancemonitoring. However, the consistent absence of influence
from serotonergic manipulation on error processing in previous
studies, including those examining feedback processing in the
absence of punishment (Barnes et al., 2011; Cools et al., 2011),
appears to discount a specific role for 5-HT in error processing.
With respect to the role of dACC in awareness of errors, we
note that the finding of significantly greater dACC activity for
aware errors compared with unaware errors is inconsistent with
previous fMRI studies of error awareness (Hester et al., 2005,
2009; Klein et al., 2007). This finding is significant because theo-
retical models have consistently implicated ACC activity in per-
formance monitoring, yet previous fMRI studies have failed to
Figure 5. BOLD activity clusters from the PLAC condition map showing significant error awareness$ drug condition interac-
tion effects. The dACC activity cluster (A) (MNI coordinates: x%(1, y% 9, z% 41) and left IPL cluster (B) (MNI coordinates: x%
(45, y%(36, z% 47) and right IPL (C) (MNI coordinates: x% 48, y%(52, z% 36) demonstrating a significant interaction
effect between error awareness (aware, unaware) and drug condition (MPH, ATM, PLAC). Bar graphs represent the mean BOLD
percentage signal change (relative to baseline) for aware and unaware errors, for the MPH, ATM, or PLAC conditions. Error bars
represent the SEM. L, Left; R, right.
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demonstrate a critical role for this region in conscious error de-
tection. ERP studies of error awareness have provided mixed re-
sults with regard to the relationship between the ERN and error
awareness (Scheffers and Coles, 2000; Nieuwenhuis et al., 2001;
Endrass et al., 2007; O’Connell et al., 2007; Steinhauser and
Yeung, 2010), with a recent review fromWessel (2012) highlight-
ing several factors that may explain these contrary findings. One
of those factors, statistical power, may in part account for our
contrary finding, with the current study being the largest yet to
test the association of error awareness and dACC activity. Previ-
ous fMRI studies demonstrated a nonsignificant trend toward
greater dACC activity during aware errors when compared with
unaware (Hester et al., 2005; Klein et al., 2007) and had effect
sizes (Hester et al., 2005, Cohen’s d' % 0.32) that would have
more probably been significant with the sample size of the cur-
rent study.
One hypothesis to account for the difference in dACC activity
between aware and unaware errors is the potential for greater
response conflict during aware error trials, for example, between
the delayed, but unsuccessful, inhibitory control response and
the subsequent error detection (or awareness) response (Nieu-
wenhuis et al., 2003). We have previously attempted to examine
the effect of the awareness response on BOLD activity by repli-
cating the stimuli and timing from the EAT task and requiring
participants tomake the awareness response after a high response
conflict trial. BOLD activity during these trials indicated signifi-
cant activity in only one functionally defined error-related ROI,
the left middle temporal gyrus, suggesting that this response re-
quirement does not account for the dACC difference (Hester et
al., 2005).However, although this control condition attempted to
capitalize on the overlearned response to the word “STOP,” it did
not require the participant to withhold their response. Future
research could test whether this response requirement accounted
for the increased dACC activity for aware errors identified by
go/no-go paradigms, by temporally dissociating the awareness
response from the no-go error event.
Human performance is inherently error prone, and, in some
cases, action errors occur without conscious awareness. This
study provides foundational evidence that the explicit awareness
of errors is dependent on activity within an error-monitoring
network, including the dACC, IPL, as well as frontal and cerebel-
lar regions. Critically, we show that the catecholamine reuptake
inhibitor MPH promotes the conscious awareness of perfor-
mance errors by strengthening activation differences within the
dACC and IPL for errors made with versus without awareness
compared with PLAC. Modulation of error awareness by the NE
reuptake inhibitor ATM was smaller in effect size and mediated
via anatomically distinct regions, including the left IFG. Con-
versely, the selective 5-HT reuptake inhibitor CIT had no signif-
icant behavioral effects, suggesting that error awareness is
particularly dependent on catecholaminergic neurotransmis-
sion. Our results have implications for our understanding of the
neurochemical underpinnings of performance monitoring and
for the pharmacological treatment of a range of disparate clinical
conditions that are marked by poor awareness of errors.
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